The disbursement improves the Company’s financial visibility. It will help accelerate the investment program for the iBiopsy® imaging platform developed by Median Technologies. The Company provides outlook for the iBiopsy® program for 2020.
Read moreMedian Technologies reports full year 2019 financial results: Revenue of €9m as of December 31, 2019, an increase of 41% compared with revenue for 2018; Order backlog of €38.3m, +61.6% compared with December 31, 2018; Cash and cash equivalents of €7.6m
Read moreAssistance Publique – Hôpitaux de Paris (AP-HP) and Median Technologies reach a research collaboration agreement involving the iBiopsy® platform. The collaboration agreement initially covers two joint clinical studies on liver cancer, involving coordinating investigators from two AP-HP hospitals -Pitié-Salpêtrière and Paul-Brousse-, and Median’s team. The agreement will enable Median to work with large patient cohorts for the clinical validation of iBiopsy®’s AI technologies.
Read more2019 full year revenue of €9 million, increased by 41% compared to 2018 full year revenue
Order backlog of €38.3 million, increased by 24.8% compared to end of H1 2019 and by 61.6% compared to end of 2018
Cash and cash equivalents of €7.6 million
To download this content please complete the form below
[contact-form-7 id="5108" title="Download file form"]